Committee advances bill allowing 12‑month birth‑control fills after debate over initial trial and cost

The House Insurance Committee on Tuesday approved House Bill 16-83, a bill that would let prescribers provide, and pharmacies fill, up to a 12‑month supply of certain contraceptive medications at once after initial trial fills.

Supporters said the measure aims to improve medication adherence by reducing pharmacy trips and lapses in therapy. “The intent is to provide full disclosure and to also reduce or eliminate fraud and protect the consumer,” Representative Roe said when introducing the bill and moving for adoption.

The bill drew extended questioning from committee members and a health‑care provider who described clinical reasons many patients switch methods during the first months after starting a new contraceptive. The provider said initial tolerability varies and clinicians commonly start with a 30‑ or 90‑day supply while a patient finds a tolerable product. “It will take five, six, seven different kinds of birth control before someone can figure out one where the side effects don’t affect them,” the provider said.

Representative Marty pressed whether the bill requires an initial short fill before a 12‑month dispensing. Committee members and the author pointed to language on page 2 that the initial fill may be a three‑month supply and that later refills can cover 12 months, explaining the bill’s intent is to allow year‑long fills for patients who have been stable on the same medication. “If this is someone who’s been stable on the same birth control for several years, this would be more appropriate,” the author said.

Several lawmakers raised concerns about cost and waste if a patient receives an expensive brand product for 12 months and then discontinues it shortly afterward. Representative Marty noted brand‑name alternatives can cost about $150 per month and cautioned that a three‑month first fill could cost $450 and be discarded if the patient stops taking it. The provider and the bill’s author responded that many generics are available for much lower prices and that pharmacies and prescribers commonly write 30‑ or 90‑day supplies for new starts.

After debate the committee held a recorded vote and advanced the bill on a 5‑2 tally. Representative Tedford was recorded as a “no” vote; the committee did not identify all individual yes/no votes on the record.

If enacted as described in committee, HB 16-83 would allow prescribers to provide an initial short fill (the bill language discussed three months) and permit subsequent fills to cover 12 months at a time for patients deemed appropriate by their providers. The bill now moves to the next committee listed on the legislative calendar.